https://orcid.org/0000-0002-7028-6062
Figures & data
Table 1. Adult patient characteristics overall and by immunocompromising conditions, US Flu VE network study, 2017–2018 (n = 5671).
Figure 1. US Flu VE Network study population, 2017–2018. Immunocompromised groups were mutually exclusive and followed the order listed here.
This Figure describes the breakdown of the study population for the US Flu VE Network for the 2017-2018 season.
There were 8900 individuals enrolled in US Flu VE during the 2017-2018 season. 44 were excluded for inconclusive RT-PCR. 115 were excluded for being influenza-negative outside of influenza circulation. 125 were excluded for being vaccinated less than 14 days prior to enrollment. 2960 were excluded for being 18 years old or younger. After those exclusions, 5656 individuals remained in the analytical dataset, of which 455 were immunocompromised and 5201 were not immunocompromised. Of the immunocompromised individuals, 19 were solid organ transplant recipients, 6 were stem cell transplants, 46 had underlying immunodeficiencies, 126 had connective tissue and/or rheumatologic conditions, 124 received chemo or radiation therapy, 105 had a hematologic condition, 105 received chronic steroids, and 9 were HIV positive. Some individuals may have had more than 1 immunocompromising condition.
Table 2. Adult influenza vaccine effectiveness, US Flu VE Network influenza, 2017–2018.
Supplemental material
Supplemental Material
Download PDF (61.2 KB)Data availability statement
Study data was provided by the Centers for Disease Control and Prevention and is available upon request.